CDMO Signal · Best CDMOs · CDMOs with the Cleanest FDA Inspection Records

CDMOs with the Cleanest FDA Inspection Records

The CDMOs that combine substantial FDA inspection experience with no unresolved compliance signals — the diligence subset for late-stage and commercial supply.

The CDMOs with the strongest FDA inspection track records combine three signals: (1) substantial inspection density — at least 3 FDA inspections on record, demonstrating actual regulator scrutiny rather than obscurity; (2) no Warning Letters — a Warning Letter is a hard signal of unresolved compliance issues and typically disqualifies a CDMO from commercial supply until formally resolved; (3) no OAI classifications — Official Action Indicated is the most serious inspection outcome. The ranking below applies all three filters to the scored CDMO population.
Filter applied: This ranking includes only CDMOs meeting all three criteria: at least 3 FDA inspections on record (demonstrating regulator scrutiny), zero FDA Warning Letters, and zero OAI (Official Action Indicated) inspection classifications. CDMOs are then ranked by composite Signal Score. Data sources: FDA Data Dashboard (inspections + 483 observations + Warning Letters). See methodology for the full scoring pillar detail.

FDA inspection posture is the single most important regulatory signal in CDMO shortlisting for programs supplying US markets. Sponsors filing under FDA jurisdiction bear direct consequences for their manufacturer's inspection record — an OAI outcome at a supplier site can halt commercial supply, trigger recall, or block product approval.

Inspection density matters as much as inspection outcome. A CDMO with 12 clean inspections on record has demonstrated compliance under sustained scrutiny; a CDMO with zero inspections has demonstrated nothing — no Warning Letters is not the same as an inspection-tested record. The filter below requires both: substantial inspection experience AND clean outcomes across all of it.

For commercial supply specifically, sponsors should also verify facility-level detail on the individual CDMO profile pages — a CDMO's aggregate record may combine sites with different histories, and the site running your program is the one that matters. This ranking is the shortlist filter; site-level diligence closes the choice.

22 qualified of 162 scored CDMOs
·
# CDMO Score FDA inspections Warning letters OAI
1 Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
91.5 4 0 0
2 Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
91.1 6 0 0
3 Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
90.9 8 0 0
4 Novartis
Basel, Switzerland
87.1 16 0 0
5 Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 3 0 0
6 City of Hope (T Cell Manufacturing)
Duarte, CA
83.9 3 0 0
7 Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
83.3 5 0 0
8 Takeda
Boston, MA · Zurich, CH
81.9 4 0 0
9 Eurofins CDMO
Planegg, DE · San Diego, CA
81.6 5 0 0
10 Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
81.1 4 0 0
11 Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
81.0 6 0 0
12 Bayer (Cell Therapy Mfg)
Berkeley, CA
80.4 8 0 0
13 Nitto Denko Avecia
Milford, MA
80.3 3 0 0
14 BioReliance (Merck)
Glasgow, UK · Rockville, MD
80.2 4 0 0
15 Bachem
Bubendorf, CH
80.0 3 0 0
16 CCRM
Toronto, ON, Canada
78.1 5 0 0
17 Biocon Biologics
Bengaluru, India
77.6 4 0 0
18 Catalent
Bagsværd, Denmark (operating under Novo Holdings)
73.1 12 0 0
19 Genezen
Indianapolis, IN · Lexington, MA
71.5 3 0 0
20 BSP Pharmaceuticals
Latina, Italy
70.5 7 0 0
21 Grand River Aseptic Manufacturing
Grand Rapids, MI
66.6 3 0 0
22 PolyPeptide Group
Torrance, CA · Strasbourg, FR · Malmo, SE
66.1 3 0 0